Naloxone: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PBAC (Australia) and PHARMAC (New Zealand), among others, recommended or restricted naloxone, while CIPM (Spain) did not recommend it.
Assessment has run over 10.8 years, from 2 Aug 2013 at AWMSG (Wales) to 2 May 2024 at PHARMAC (New Zealand).
PHARMAC (New Zealand) changed its position: restricted on 2 May 2024, recommended by 2 May 2024.
No assessment is on file from SMC (Scotland) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 5 of 11 records date from 2023 or later.
3 distinct indication wordings are recorded for naloxone by the agencies that label one in English (AWMSG and PBAC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess naloxone, on 2 Aug 2013; PHARMAC (New Zealand) did not open a file until 2 May 2024 — an unusually long tail of 10.8 years between the earliest and latest system to look at it.
3 of the 6 agencies here assessed naloxone more than once, PHARMAC (New Zealand) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for naloxone.
The full ledger for naloxone reads 7 recommended, 2 not assessed, 1 restricted and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 2 May 2024 | Reversal of opioid overdose, use by emergency medical service personnel | PTAC advice: Low | source |
| HAS (France) | 27 Mar 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| CIPM (Spain) | 23 Oct 2023 | Indicación terapéutica autorizada: Indicada en adultos, adolescentes, niños y lactantes de más de 4 kg de peso para: Rev… | not financed by the SNS · art. 92 a | source |
| AWMSG (Wales) | 8 Dec 2021 | Ventizolve is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manif… | outside AWMSG criteria | source |
| PBAC (Australia) | 2019 | Known or suspected opiate overdose | The PBAC recommended the dual General Schedule and Section 100 listing of intranasal nalox… | source |
6 further decisions for naloxone, across 4 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- sevelamer — same ATC class V03A — Other therapeutic products
- deferasirox — same ATC class V03A — Other therapeutic products
- patiromer — same ATC class V03A — Other therapeutic products
- deferiprone — same ATC class V03A — Other therapeutic products
- difelikefalin — same ATC class V03A — Other therapeutic products
- andexanet alfa — same ATC class V03A — Other therapeutic products
Coverage: 11 decisions for naloxone from 6 agencies, 2013 to 2024. Data to 7 Sep 2026. ATC class V03A — Other therapeutic products. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.